Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to study enrollment~* A candidate for phototherapy or systemic therapy~* For the extension study: must have completed Part 3 of the base study~* For the extension study: must have achieved at least a PASI-50 response by the end of Part 3 of the base study~* For the extension study: must have received active tildrakizumab (MK-3222) treatment within 12 weeks prior to the end of Part 3 of the base study~* Premenopausal female participants must agree to abstain from heterosexual activity or use a medically accepted method of contraception or use appropriate effective contraception as per local regulations or guidelines~* If enrolled at a Japanese site, participants with psoriatic arthritis using non-steroidal anti-inflammatory drugs (NSAIDs) must be on a stable dose for at least 4 weeks prior to the first dose of study drug and must not be expected to require an increase in dose over the course of the study~Exclusion Criteria:~* Has erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis~* Current or history of severe psoriatic arthritis and is well-controlled on current treatment~* Women of child-bearing potential who are pregnant, intend to become pregnant within 6 months of completing the trial, or who are breast feeding~* Expected to require topical treatment, phototherapy, or systemic treatment during the trial~* Presence of any infection~* History of recurrent infection requiring treatment with systemic antibiotics within 2 weeks of screening~* Previous use of tildrakizumab (MK-3222) or other IL-23/Th-17 pathway inhibitors including P40, p19, and IL-17 antagonists~* Evidence of active or untreated latent tuberculosis (TB)~* Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)~* At Japanese sites, positive test for HBs antibody and hepatitis B virus (HBV) deoxyribonucleic acid (DNA)~* At Japanese sites, positive test for the Hepatitis B core (HBc) antibody and HBV DNA~* For the extension study: women of child-bearing potential who are pregnant, intend to become pregnant within 6 months of completing the trial, or who are breast feeding~* For the extension study: active or uncontrolled significant organ dysfunction or clinically significant laboratory abnormalities~* For the extension study: expected to require topical treatment, phototherapy, or systemic treatment during the extension study~* At Japanese sites, abnormal for Beta D Glucan and/or KL-6 test result(s) at the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tildrakizumab 200 mg (Type: EXPERIMENTAL): Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.
- Tildrakizumab 100 mg (Type: EXPERIMENTAL): Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo administered SC once a week at Weeks 0 and 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).